Atorvastatin evaluated for dyslipidemia in children with steroid-sensitive nephrotic syndrome

This quasi-experimental study, conducted at the department of Pediatric Nephrology & Nephrology, National Institute of Kidney Diseases & Urology, Dhaka, aimed to evaluate the effectiveness and safety of atorvastatin therapy in children with dyslipidemia in steroid-sensitive nephrotic syndrome (SSNS). The study enrolled 100 children aged between 8-18 years with SSNS and dyslipidemia. The background notes that dyslipidemia is a common complication in children with SSNS, often persists during remission, and increases the risk of early atherosclerosis, cardiovascular disease, and progressive kidney damage. It states that lifestyle and dietary measures are often insufficient and that evidence on statin use in this population remains fairly unexplored. The primary outcome measure was the percentage of patients achieving target levels of lipid profile. The study status is listed as COMPLETED, with a start date of January 27, 2024, and a primary completion date of August 30, 2025. The abstract does not provide any specific numerical results regarding the primary outcome, changes in lipid parameters, safety signals, adverse events, or statistical analyses (such as p-values, confidence intervals, hazard ratios, or odds ratios). No limitations of the study are mentioned in the provided abstract text.

For children with a kidney condition called steroid-sensitive nephrotic syndrome, the problem isn't just their kidneys. A common and dangerous complication is dyslipidemia—unhealthy levels of cholesterol and fats in the blood. This often sticks around even when the main kidney symptoms are in remission. It's a silent threat that raises the risk of early heart disease and further kidney damage. Dietary changes often aren't enough, and there's little evidence on whether cholesterol-lowering drugs called statins are safe and effective for these kids. This study aimed to fill that gap. It looked specifically at the drug atorvastatin in 100 children, aged 8 to 18, who had this kidney condition and the accompanying cholesterol problem. The main goal was to see what percentage of these children could reach healthier, target levels for their cholesterol and other blood fats after taking the drug. The study also carefully monitored for safety. The findings could provide much-needed guidance on whether this common adult medication can be a safe and useful tool to protect the long-term heart and kidney health of vulnerable children.